Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)

To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and bevacizumab in newly diagnosed stage III or IV ovarian cancer (OC). METHODS: This multicenter placebo-controlled double-blind randomized phase III tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Moore, Kathleen N., Bookman, Michael, Sehouli, Jalid, Miller, Austin, Anderson, Charles, Scambia, Giovanni, Myers, Tashanna, Taskiran, Cagatay, Robison, Katina, Mäenpää, Johanna, Willmott, Lyndsay, Colombo, Nicoletta, Thomes-Pepin, Jessica, Liontos, Michalis, Gold, Michael A., Garcia, Yolanda, Sharma, Sudarshan K., Darus, Christopher J., Aghajanian, Carol, Okamoto, Aikou, Wu, Xiaohua, Safin, Rustem, Wu, Fan, Molinero, Luciana, Maiya, Vidya, Khor, Victor K., Lin, Yvonne G., Pignata, Sandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
RAPID COMMUNICATIONS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189598/
https://www.ncbi.nlm.nih.gov/pubmed/33891472
http://dx.doi.org/10.1200/JCO.21.00306

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189598/
https://www.ncbi.nlm.nih.gov/pubmed/33891472
http://dx.doi.org/10.1200/JCO.21.00306

Ejemplares similares